We are live on ! Find out more
CRXT

Clarus Therapeutics Holdings, Inc. Common Stock
CRXT

Delisted

CRXT was delisted on the 30th of August, 2022.

Back to rankings

33 hedge funds and large institutions have $50.6M invested in Clarus Therapeutics Holdings, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

57% more funds holding

Funds holding: 21 → 33 (+12)

35% more capital invested

Capital invested by funds: $37.6M → $50.6M (+$13M)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

Holders
33
Holders Change
+12
Holders Change %
+57.14%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
5
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
YCM
Yakira Capital Management
Connecticut
+$2.47M
2
BFM
Boothbay Fund Management
New York
+$2.45M
3
LCM
Landscape Capital Management
New Jersey
+$1.16M
4
SCM
Saba Capital Management
New York
+$1.02M
5
SCM
Shaolin Capital Management
Florida
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$854K
2
II
Ibex Investors
Colorado
-$351K
3
CCA
Cruiser Capital Advisors
Connecticut
-$201K
4
MSU
Mizuho Securities USA
New York
-$71.8K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$17.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIM
1
Karpus Investment Management
New York
$7.76M +$724K +71,863 +10%
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$4.13M -$854K -84,866 -17%
CH
3
CVI Holdings
Delaware
$4.03M – – –
MP
4
Mangrove Partners
Connecticut
$2.88M – – –
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$2.77M – – –
MSU
6
Mizuho Securities USA
New York
$2.77M -$71.8K -7,130 -3%
SCM
7
Saba Capital Management
New York
$2.73M +$1.02M +101,246 +60%
YCM
8
Yakira Capital Management
Connecticut
$2.47M +$2.47M +245,000 New
ASM
9
ATW SPAC Management
New York
$2.45M +$2.45M +243,417 New
BFM
10
Boothbay Fund Management
New York
$2.45M +$2.45M +243,417 New
RCM
11
Radcliffe Capital Management
Pennsylvania
$2.27M – – –
BI
12
Bulldog Investors
New Jersey
$2.19M – – –
Bank of America
13
Bank of America
North Carolina
$1.59M – – –
PC
14
Periscope Capital
Ontario, Canada
$1.41M +$42.3K +4,200 +3%
RCM
15
Rivernorth Capital Management
Florida
$1.26M – – –
LCM
16
Landscape Capital Management
New Jersey
$1.17M +$1.16M +115,642 New
SCM
17
Shaolin Capital Management
Florida
$1.01M +$1.01M +100,000 New
AA
18
AQR Arbitrage
Connecticut
$914K +$309K +30,678 +51%
WRBC
19
W.R. Berkley Corp
Connecticut
$825K +$823K +81,791 New
Millennium Management
20
Millennium Management
New York
$574K +$574K +56,987 New
FTCM
21
Fir Tree Capital Management
New York
$438K – – –
CCM
22
Context Capital Management
California
$387K -$13.3K -1,321 -3%
DWM
23
Dakota Wealth Management
Florida
$338K – – –
SSA
24
Schonfeld Strategic Advisors
New York
$302K +$192K +19,026 +173%
Walleye Trading
25
Walleye Trading
New York
$301K +$300K +29,838 New
1
2

CRXT Hedge Fund Activity: Q2 2021 in Review

33 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) for Q2 2021, worth a combined $50.6M — up 35% from $37.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new CRXT positions and 2 closed out — a net gain of 12 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Yakira Capital Management, opening a new position worth an estimated $2.47M. The largest seller was Hudson Bay Capital Management, cutting an estimated $854K.

  • 33 institutional investors held Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) as of Q2 2021, up from 21 in Q1 2021.
  • Funds reported $50.6M of Clarus Therapeutics Holdings, Inc. Common Stock stock for Q2 2021, up 35% quarter-over-quarter.
  • 14 funds opened new Clarus Therapeutics Holdings, Inc. Common Stock positions in Q2 2021 and 2 closed out, a net change of +12 holders.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock buyer in Q2 2021 was Yakira Capital Management, an estimated $2.47M added.
  • The largest Clarus Therapeutics Holdings, Inc. Common Stock seller in Q2 2021 was Hudson Bay Capital Management, an estimated $854K sold.

Based on aggregated 13F filings for Q2 2021.